Home › Investor Centre › Investor news › Regulatory Announcements 2009
16 November 2009 - New Research Collaboration with Pharmsynthez
10 November 09 Additional listing
01 October 09 Additional listing and Total Voting Right
30 September 09 Lipoxen Appointed Lead for Vaccine Programme Grant
30 September 09 Senior Management Appointment
30 September 09 Interim Results for the six months ended 30 June 2009
15 September 09 Additional Listing
04 August 09 Director/PDMR Shareholding
24 July 09 Audit and Remuneration Committee Membership
24 July 09 Result of AGM
20 July 09 Director Shareholding
02 July 09 Notice of Annual General Meeting
29 June 2009 Patent Granted
23 June 09 New Evaluation Agreement Signed with Major Pharma Company
29 May 09 Director Dealings
29 May 09 £2.9 million fundraising
29 May 09 $1m Investment from Baxter
13 May 09 Malaria Vaccine Agreements
06 May 09 Positive Phase I Clinical Trial Data
30 April 09 Positive Data for Revolutionary Influenza Vaccine
01 April 09 Appointment of Joint Broker
01 April 09 Change of Nominated Advisor & Joint Broker
19 March 09 Lipoxen enters into agreement with Glide Pharma
09 March 09 Sulixen Phase I Results
03 March 09 Holdings In Company
15 January 09 Interim Phase I Results - Long Acting EPO
Back to Investor news